Peptides and the NHS: What Your GP Needs to Know

Several peptide-based medications are fully licensed and prescribable by UK GPs, either directly or via shared care arrangements.

GLP-1 agonists (metabolic/diabetes): - Semaglutide (Ozempic): Prescribable by GPs for Type 2 diabetes; Wegovy (weight management) requires Tier 3 specialist initiation - Tirzepatide (Mounjaro): Licensed for T2D and weight management; NHS access via shared care in some ICBs; private prescribing widely available - Liraglutide (Victoza/Saxenda): Victoza for T2D prescribable in primary care; Saxenda (weight management) requires specialist initiation - Dulaglutide (Trulicity): Prescribable in primary care for T2D - Exenatide (Byetta/Bydureon): Older GLP-1 agent; prescribable in primary care for T2D

Bone and metabolism: - Teriparatide (Forsteo): A fragment of parathyroid hormone (PTH 1–34); licensed for severe osteoporosis; initiated by specialists but can be continued in primary care

Important distinction: These are licensed medicines prescribed within their approved indications. They are entirely different from research peptides (BPC-157, TB-500, CJC-1295, etc.) which are not licensed as medicines and cannot be prescribed by GPs.

*This article is for educational purposes only. Always consult your GP or specialist about medication eligibility and prescribing.*

Many patients are unsure how to raise the topic of peptide-based treatment with their GP, particularly for weight management or metabolic health. A structured, factual approach works best.

For licensed peptide medications (GLP-1s, teriparatide): - Be specific: 'I've been reading about semaglutide/tirzepatide for weight management — am I eligible under current NICE guidelines?' - Bring your BMI calculation and any relevant comorbidity information (blood pressure readings, blood test results if you have them) - Reference NICE guidance by number if you have done your research: TA875 (semaglutide weight management), TA924 (tirzepatide T2D) - Ask about Tier 3 referral pathways if your GP confirms NHS eligibility

Useful phrases: - 'I understand this requires specialist initiation — can you refer me to the local weight management service?' - 'I have Type 2 diabetes and my HbA1c isn't well controlled — is semaglutide or tirzepatide an option for me?' - 'I'm considering private prescribing — can you support with blood test monitoring whilst I access medication privately?'

Managing GP reluctance: Some GPs are cautious about newer medications or may be unfamiliar with the latest NICE approvals. Politely noting that the medication is NICE-approved is appropriate. If you continue to experience difficulty, requesting a referral to a weight management specialist or endocrinologist is a reasonable escalation.

What GPs cannot do: - Prescribe licensed GLP-1s outside their approved indications (e.g., prescribing Ozempic solely for weight loss in a non-diabetic patient) - Prescribe research peptides (BPC-157, PT-141, etc.) — these are not licensed medicines

Whether you are taking a licensed GLP-1 medication or using research peptides, appropriate blood test monitoring is important for safety.

Standard monitoring for GLP-1 agonists (NHS or private): - HbA1c (glycated haemoglobin) — baseline and at 3–6 months to assess glycaemic response (primarily for T2D patients) - eGFR / creatinine — kidney function; GLP-1 medications are generally renal-protective but baseline assessment is good practice - Liver function tests (LFTs) — routine metabolic monitoring - Lipid profile — weight loss medications often improve lipids; useful baseline - Thyroid function (TSH) — semaglutide and tirzepatide carry a theoretical thyroid C-cell tumour risk (primarily from animal studies); thyroid monitoring is appropriate in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN2 - Blood pressure and heart rate — important as weight loss changes cardiovascular parameters

Requesting monitoring from your GP: - In primary care, GPs can order a standard metabolic panel including all of the above - State clearly what you are taking: 'I am taking [medication name] and would like a monitoring blood test — can I have HbA1c, renal function, LFTs and lipids?' - If your GP is supportive but unfamiliar with the monitoring protocol, the prescribing clinic (if private) should provide a monitoring letter or protocol

For patients using research peptides: - Research peptides are not licensed medicines; GPs are not obligated to monitor specifically for their use - However, general health monitoring (liver function, kidney function, full blood count) can be requested on routine clinical grounds - Be aware that some GPs may decline to engage with research peptide monitoring — private health screening services are an alternative

This is one of the most practically important questions for people using research peptides: should you tell your GP?

The case for disclosure: - Your GP needs an accurate medication list to avoid drug interactions — some peptides affect metabolism, coagulation, blood pressure or hormones - If you experience a side effect or adverse reaction, your GP cannot give appropriate advice without knowing what you are taking - Certain peptides affect blood test results — for example, growth hormone-releasing peptides (sermorelin, ipamorelin) affect IGF-1 and glucose levels; disclosing use allows correct interpretation - Pre-surgical assessment — anaesthetists need to know all substances being used before surgery - Professional confidentiality: your GP cannot report you to the police for personal research peptide use (possession of most research peptides is not a criminal offence in the UK, though supply is regulated)

Practical framing for disclosure: - You do not need to apologise or over-explain; simply include research peptides on your medication list as factually as possible - 'I'm also using BPC-157 peptide — I wanted you to be aware in case it affects any test results or medication decisions' - Your GP may be unfamiliar with the compound; do not expect them to have expert knowledge, but disclosure protects your safety

When disclosure may be less critical: - If the peptide has no plausible interaction with your current medications and you are having no concerning symptoms, the clinical urgency is lower - However, pre-operatively and in any acute illness, always disclose everything you are taking

Many patients with an interest in peptide-based therapy end up navigating a combination of NHS and private care. Understanding how these systems interact helps you get the best of both.

NHS prescribing for licensed peptides: - Offers access to licensed GLP-1 medications at NHS prescription cost (or free if you qualify for medical exemption) - Provides ongoing monitoring within a clinical framework - The primary limitation is access speed and availability — waiting times for specialist weight management services can be significant, and supply shortages are ongoing

Private prescribing: - Faster access; most telehealth providers can initiate treatment within days - Costs £150–£300/month for medication plus consultation fees - Reputable private prescribers should still conduct proper clinical assessments, monitoring, and follow-up - Private prescriptions can sometimes be dispensed on the high street (some NHS pharmacies can dispense private prescriptions for licensed medications)

Using both systems simultaneously: - It is entirely legal and common to use private prescribing for a licensed medication whilst maintaining NHS GP monitoring - Inform your GP if you are taking privately prescribed medications — this is important for your medical record and safety - Your GP can order monitoring blood tests on NHS grounds without necessarily being the prescriber - If your private treatment produces good clinical outcomes, some GPs will take over prescribing on NHS when eligible (e.g., if you now have a qualifying BMI or HbA1c indication)

Summary guidance: Be transparent with your GP about everything you are taking — licensed or otherwise. The NHS and private systems can complement each other effectively when your GP has an accurate picture of your health and treatment.

*This article is for educational purposes only and does not constitute medical or legal advice. Consult your GP or a qualified prescriber for personalised guidance.*